Abstract
Adrenocortical carcinoma (ACC) is a rare, aggressive tumor that is often detected in an advanced stage. Medical treatment with the adrenotoxic drug mitotane has been used for decades, but critical prospective trials on its role in residual disease or as an adjuvant agent after surgical resection are still lacking. The concept of a critical threshold plasma level of the drug must be confirmed in controlled studies. Because individual responsiveness cannot be predicted, the use mitotane is still advised for nonresectable disease. In case of Cortisol or other steroid overproduction, several drugs (e.g., ketoconazole or aminoglutethimide) may be used. Chemotherapy with single agents (e.g., doxorubicin or cisplatin) have been disappointing, with low response rates (< 30%) and a short response duration. Part of this refractoriness may be explained by the fact that ACC tumors express the multidrug-resistance gene MDR-1. Chemotherapy with multiple agents has been tested in smaller series and has resulted in significant side effects. The best results were achieved by the combination of etoposide, doxorubicin, and cisplatin associated with mitotane, achieving a response rate of 54%, including individual complete responses. To be able to make progress in treating advanced ACC disease, adjuvant multicenter trials must be encouraged. When mitotane-based therapies are used, monitored drug levels are mandatory.
Résumé
Le cancer de la corticosurrénale (CCS) est une tumeur rare mais agressive, détectée souvent à un stade avancé. Le traitement médical par le mitotane, une drogue adrénotoxique, est utilisée depuis plusieurs décennies, mais, on manque d’essais prospectifs critiques sur son rôle dans la maladie résiduelle ou comme agent adjuvant après résection chirurgicale. Le concept d’un niveau plasmatique dont le seuil critique doit être confirmé par des études contrôlées. Puisqu’on ne peut prédire la réponse individuelle, le mitotane est toujours conseillé dans les maladies nonréséquables. En cas d’hyperproduction de Cortisol, ou d’autres Steroides, d’autres drogues, comme par exemple, le cétoconazole ou l’aminogluthétimide peuvent être utilisées. La monochimiothérapie, avec par exemple la doxorubicine et le cisplatine, est décevante avec un taux de réponse bas (<30%) et une durée de réponse courte. Une partie de cette non-réonse peut être expliquée par le fait que les CCS expriment un gène de résistance multidrogues, le MDR-1. La plurichimiothérapie a été testée dans de plus petites séries avec des effets secondaires importants. Les meilleurs résultats ont été avec la combinaison d’étoposide, de doxorubicine et de cisplatine associés au mitotane: le taux de réponse a été de 54%, avec quelques réponses individuelles complètes. Pour faire des progrès dans le CCS avancé, il faut encourager des essais multicentriques de traitement adjuvant. En cas de thérapie utilisant le mitotane, il faut obligatoirement monitorer le taux des drogues.
Resumen
El carcinoma adrenocortical (CAC) es un tumor agresivo poco frecuente que comûnmente se détecta cuando ya esta en etapas avanzadas de su desarrollo. Desde hace décadas se practica tratamiento médico con una droga adrenotöxica, el mitotane, pero no se dispone de ensayos clînicos prospectivos que soporten su valor en enfermedad residual o como adyuvante de la resection quirürgica. También se hace necesario confirmar el concepto de nivelés criticos de la droga mediante estudios controlados. Puesto que no es posible predecir la respuesta individual, todavia se aconseja el uso del mitotane en casos de enfermedad no resecable. Cuando hay superproduction de Cortisol o de otros esteroides, se pueden utilizar algunas drogas como el Ketoconazol o la aminoglutetimida. La quimioterapia con agentes ûnicos, por ejemplo doxorubicina y el cisplatino, ha sido decepcionante, por las bajas tasas (<30%) y la corta duration de la respuesta. Parte de tal situation refractaria puede explicarse por el hecho de que los CAC expresan el gen MDR-1 de resistencia multidroga. La quimioterapia con agentes multiples ha sido ensayada en series mas pequenas, con efectos secundarios significatives. Los mejores resultados se logran con la combination de etopösido, doxorubicina y cisplatino asociada con mitotane, alcanzando una tasa de respuesta del 54%, incluyendo respuestas complétas. Para lograr progreso en el manejo del CAC avanzado se debe estimular la realization de ensayos multi-institucionales. La monitoria de los nivelés de droga son obligatorios cuando se usan terapias con base en mitotane.
Similar content being viewed by others
References
Gröndal, S, Cedermark, B., Eriksson, B., Grimelius, L., Harach, R., Kristoffersson, A., Rastad, J., Udén, P., Åkerström, G.: Adrenocortical carcinoma: a retrospective study of a rare tumor with poor prognosis. Eur. J. Surg. Oncol. 16:500, 1990
Khorram-Manesh, A., Ahlman, H., Jansson, S., Wängberg, B., Nilsson, O., Jakobsson, CE., Eliasson, B., Lindstedt, S., Tisell, L.E.: Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J. Surg. 22:605, 1998
MacFarlane, D.A.: Cancer of the adrenal cortex: the natural history, prognosis and treatment in a study of fifty-five cases. Ann. R. Coll. Surg. Engl. 25:155, 1958
Sullivan, M., Bojkan, M., Hodges, C.V.: Adrenal cortical carcinoma. J. Urol. 720:660, 1978
Henley, D.J., van Heerden, J. A., Grant, CS., Carney, JA., Carpenter, P.C.: Adrenal cortical carcinoma: a continuing challenge. Surgery 94:926, 1983
Kasperlik-Zaluska, A.A., Migdalska, B.M., Zgliczynski, S., Makowska, A.M.: Adrenocortical carcinoma: a clinical study and treatment result of 52 patients. Cancer 75:2587, 1995
Wooten, M.D., King, D.K.: Adrenal cortical carcinoma: epidemiology and treatment with mitotane and a review of the literature. Cancer 72:3145, 1993
Lipsett, M.B., Hertz, R., Ross, G.T.: Clinical and pathophysiologic aspects of adrenocortical carcinoma. Am. J. Med. 55:374, 1963
Hough, A.J., Hollifield, J.W., Page, D.L., Hartmann, W.H.: Prognostic factors in adrenal cortical tumors. Am. J. Pathol. 8:163, 1984
Luton, J.P., Cerdas, S., Billaud, L., Thomas, G., Guihaume, B., Bertagna, X., Laudat, M.H., Louvel, A., Chapuis, Y., Blandeau, P., Bonnin, A., Bricaire, H.: Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapv. N. Engl. J. Med. 322:1195, 1990
Icard, P., Chapuis, Y., Andreassian, B., Bernard, A., Prove, C: Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgeons. Surgery 772:972, 1992
Cohn, K., Gottesman, L., Brennan, M.: Adrenocortical carcinoma. Surgery 100:1170, 1986
Pommier, R.F., Brennan, M.F.: An eleven-year experience with adrenocortical carcinoma. Surgery 772:963, 1992
Lubitz, JA., Freeman, L., Okun, R: Mitotane use in inoperable adrenal cortical carcinoma. JAMA. 225:1109, 1973
Schteingart, D.E., Motazedi, A., Noonan, RA., Thompson, N.W.: Treatment of adrenal carcinoma. Arch. Surg. 777:1142, 1982
Hoffmann, D.L., Mattox, V.R.: Treatment of adrenocortical carcinoma with o,p′-DDD. Med. Clin. North Am. 56:999, 1972
Decker, RA., Elson, P., Hogan, T.E., Citrin, D.L., Westring, D.W., Banerjee, T.K., Gilchrist, K.W., Horton, J., Eastern Cooperative Oncology Group,: Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110:1006, 1991
Bukowski, R.M., Wolfe, M., Levine, H.S., Crawford, D.E., Stephens, R.L., Gaynor, E., Harker, W.G.: Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J. Clin. Oncol. 7:161, 1993
Fallo, F., Pilon, C., Barzon, L., Pistorello, M., Pagotto, U., Atavilla, G., Boscaro, M., Sonino, N.: Effects of taxol on the human NC1-H295 adrenocortical carcinoma cell line. Endocr. Res. 22:709, 1996
Beruti, A., Terzolo, M., Pia, A., Angeli, A., Dogliotti, L., Italian Group for the Study of Adrenal Cancer,: Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer 55:2194, 1998
Percarpio, B., Knowlton, A.H.: Radiation therapy of adrenal cortical carcinoma. Acta Radiol. Ther. Phys. Biol. 75:288, 1976
King, D.R., Lack, E.E.: Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases. Cancer 44:239, 1979
Didolkar, M.S., Bescher, A., Elias, E.G., Moore, R.H.: Natural history of adrenal cortical carcinoma. Cancer 47:2153, 1981
Bergenstal, D.M., Hertz, R., Lipsett, M.B., Moy, R.H.: Chemotherapy of adrenocortical cancer with o,p′-DDD. Ann. Intern. Med. 55:672, 1960
Trainer, P.J., Besser, M.: Cushing’s syndrome: therapy directed at the adrenal glands. Endocrinol. Metab. Clin. North Am. 25:571, 1994
Hutter, A.M., Jr., Kayhoe, D.E.: Adrenal cortical carcinoma: results of treatment with o,p′ DDD in 138 patients. Am. J. Med. 47:581, 1966
Boven, E., Vermorken, J.B., van Slooten, H., Pinedo, H.M.: Complete response of metastasized adrenal cortical carcinoma with o,p′-DDD: case report and literature review. Cancer 55:26, 1984
Plager, J.E.: Carcinoma of the adrenal cortex: clinical description, diagnosis, and treatment. Int. Adv. Surg. Oncol. 7:329, 1984
Venkatesh, S., Hickey, R.C., Sellin, R.V., Fernandez, J.F., Samaan, N.A.: Adrenal cortical carcinoma. Cancer 64:765, 1989
Vassilopoulou-Sellin, R., Guinée, V., Klein, M.J., Taylor, S.H., Hess, K.R., Schultz, P.N., Samaan, N.A.: Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 77:3119, 1993
Barzon, L., Fallo, F., Sonino, N., Daniele, O., Boscaro, M.: Adrenocortical carcinoma: experience in 45 patients. Oncology 54:490, 1997
Barzon, L.: Is there a role for low doses of mitotane as adjuvant therapv in adrenocortical carcinoma? J. Clin. Endocrinol. Metab. 54:1488, 1999
Van Slooten, H., Moolenaar, A.J., Van Seters, A.P., Smeenk, D.: The treatment of adrenocortical carcinoma with o,p′-DDD: prognostic implications of serum level monitoring. Eur. J. Cancer Clin. Oncol. 20:47, 1984
Haak, H. R., Hermans, J., Van de Velde, C.J., Lentjes, E.G., Gosling, B.M., Fleuren, G.J.: Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br. J. Cancer 69:947, 1994
Verhelst, J.A., Trainer, P.J., Howlett, TA., Perry, L., Rees, L.H., Grossman, A.B., Wass, J.A., Besser, G.M.: Short-and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin. Endocrinol. (Oxf.) 55:169, 1991
Sonino, N., Boscaro, M., Paolette, A., Mantero, F., Ziliotto, D.: Ketoconazole treatment in Cushing’s syndrome: experience in 34 patients. Clin. Endocrinol. (Oxf.) 35:347, 1991
Sinnaeve, L.J.E., Becks, G.P.: Preoperative ketoconazole therapy for adrenocortical carcinoma. Can. Med. Assoc. J. 141:131, 1989
Contreras, P., Rojas, A., Biagini, L., Gonzalez, P., Massardo, T.: Regression of metastatic adrenal carcinoma during palliative ketoconazole treatment. Lancet 2:151, 1985
Bertagna, X., Basin, C., Picard, F., Varet, B., Bertagna, C., Hucher, M., Luton, P.: Peripheral antiglucocorticoid action of RU 486 in man. Clin. Endocrinol. (Oxf.) 25:537, 1988
Nieman, L.K., Chrousos, G.P., Kellner, C., Spitz, I.M., Nisula, B.C., Cutter, G.B., Merriam, G.R., Bardin, C.W., Loriaux, D.L.: Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J. Clin. Endocrinol. Metab. 67:536, 1985
Norton, J.A., Levin, B., Jensen, R.T.: Cancer of the endocrine system. In Principles and practice of Oncology (4th edition), De Vita, V.T., Jr., Hellmann, S., Rosenberg, S.A., editors, Philadelphia, Lippincott 1993, pp. 1333
Bates, S.E., Shieh, C.Y., Mickley, L.A., Dichek, H.L., Gazdar, A., Loriaux, D.L., Fojo, AT.: Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-l/P glycoprotein) which is also expressed by adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 75:18, 1991
Flynn, S.D., Murren, J.R., Kirby, W.M., Hong, J., Kan, I., Kinder, B.K.: P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 772:981, 1992
Andres, F., Grunenberger, F., Kurtz, J.E., Goichot, B., Dufour, P., Schlienger, J.L.: Le traitement du cortico-surrénalome malin. Presse Med. 26:880, 1997
Teicher, B.A.: Lonidamine: in vitro/in vivo correlations. Eur. J. Cancer 30:1411, 1994
Feuillau, P., Raffeld, M., Stein, CA., Lipford, N., Rehnquist, D., Meyers, CE., La Rocca, R.V., Chrousos, G.P.: Effects of suramin on the function and structure of the adrenal cortex in the cynomolgus monkey. J. Clin. Endocrinol. Metab. 65:153, 1987
Allolio B., Reincke, M., Arlj, W., Deuss, U., Winkelmann, W., Siekmann, L.: Suramin for treatment of adrenal carcinoma. Lancet 7:277, 1989
La Rocca, R.V., Stein, CA., Danesi, R., Tannis Dow, CA., Weiss, G.H., Meyers, CE.: Modulation of steroid hormone production, cytotoxicity in vitro and clinical antitumor effect. J. Clin. Endocrinol. Metab. 71:497, 1990
Wu, Y.W., Chik, CL., Knazek, R.A.: An in vitro and in vivo study of antitumour effects of gossypol on human SW-13 adrenocortical carcinoma. Cancer Res. 49:3154, 1989
Flack, M.R., Pyle, R.G., Mullen, N.M., Lorenzo, B., Wu, Y.W., Knazek, R.A., Nisula, B.C., Reidenberg, M.M.: Oral gossypol in the treatment of metastatic adrenal cancer. J. Clin. Endocrinol. Metab. 76:1019, 1993
Benz, C.C., Keniry, M.A., Ford, J.M., Townsend, A.J., Cox, F.W., Palayoor, S., Matlin, S.A., Hait, W.N., Cowan, K.H.: Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Mol. Pharmacol. 37:840, 1990
Haq, M.M., Legha, S.S., Samaan, N.A., Bodey, G.P., Burgess, M.A.: Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat. Rep. 64:909, 1980
Chun, H.G., Yogoda, A., Kemeny, N.: Cisplatinum for adrenal cortical carcinoma. Cancer Treat. Rep. 67:513, 1983
Hesketh, P.J., McCaffrey, R.P., Finkel, H.E., Lamon, S.S., Griffing, G.T., Melby, J.C.: Cisplatin based treatment of adrenocortical carcinoma. Cancer Treat. Rep. 77:2221, 1987
Tattersall, M.H., Lander, H., Bain, B., Stocks, A.E., Woods, R.L., Fox, R.M.: Cisplatin treatment of metastatic adrenal carcinoma. Med. J. Aust. 7:419, 1980
Van Slooten, H., Van Osterom, A.T.: CAP (cyclophosphamide, doxorubicin and cisplatin) resimen in adrenal cortical carcinoma. Cancer Treat. Rep. 67:377, 1983
Schlumberger, M., Brugières, L., Gicquel, C., Travagli, J.P., Droz, J.P., Parmentier, C.: 5-Fluorouracil, doxorubicin and cisplatin as treatment for adrenal cortical carcinoma. Cancer 67:2997, 1991
Johnson, D.H., Greco, F.A.: Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP16). Cancer 55:2198, 1986
Burgess, M.A., Legha, S.S., Sellin, R.V.: Chemotherapy with cisplatinum and etoposide (UP16) for patients with advanced adrenal cortical carcinoma (ACC). Proc. Ann. Soc. Clin. Oncol. 72:188, 1993
Zidon, J., Stipendier, M., Robinson, E.: Treatment of metastatic adrenal cortical carcinoma with etoposide (VP16) and cisplatin after failure with o.p.′DDD. Am. J. Clin. Oncol. 79:229, 1996
Bonacci, R., Gigliotti, A., Baudin, E., Wion-Barbot, N., Emy, P., Bonsay, M., Cailleux, A.F., Nakib, I., Schlumberger, M., Résan Comète INSERM,: Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br. J. Cancer 75:546, 1998
Gebhardt, D.O.E., Moolenar, A.J., van Seters, A.P., van der Velde, E.A., Gevers Leuven, J.A.: The distribution of o,p′-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia. Cancer Chemother. Pharmacol. 29:331, 1992
Preusser, P., Wilke, H., Achterrath, W., Fink, U., Lenaz, L., Heinicke, A., Meyer, J., Meyer, HJ., Buente, H.: Phase II study with the contribution of etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J. Clin. Oncol. 7:1310, 1989
Villa, R., Orlandi, L., Berrutti, A., Dogliotti, L., Zaffaroni, N.: Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cell. Int. J. Oncol. 74:133, 1999
Carpenter, P.C.: Mitotane failure in adrenocortical cancer: where next? Cancer 77:2900, 1993
Bergström, M., Bonasera, T.A., Lu, L., Bergström, E., Backlin, C., Juhlin, C., Långström, B.: In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J. Nucl. Med. 59:982, 1998
Gicquel, C., Raffin-Sanson, M.L., Gaston, V., Bertagna, X., Plovin, P.F., Schlumberger, M., Louvel, A., Luton, J.P., Le Bouc, Y.: Structural and functional abnormalities at lip 15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J. Clin. Endocrinol. Metab. 52:2559, 1997
Author information
Authors and Affiliations
Corresponding author
Additional information
Published Online: June 27, 2001
Rights and permissions
About this article
Cite this article
Ahlman, H., Khorram-Manesh, A., Jansson, S. et al. Cytotoxic treatment of adrenocortical carcinoma. World J. Surg. 25, 927–933 (2001). https://doi.org/10.1007/s00268-001-0031-6
Issue Date:
DOI: https://doi.org/10.1007/s00268-001-0031-6